Does the media favor CBLL or PROF?

In the previous week, CeriBell had 16 more articles in the media than Profound Medical. MarketBeat recorded 18 mentions for CeriBell and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat CeriBell's score of 0.78 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBNX or PROF?

In the previous week, Beta Bionics had 2 more articles in the media than Profound Medical. MarketBeat recorded 4 mentions for Beta Bionics and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat Beta Bionics' score of 0.55 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, INMD or PROF?

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.30 $93.83M $1.23 12.07 Profound Medical $16.10M 15.46 -$42.57M -$0.98 N/A

Is INMD or PROF more profitable?

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% Profound Medical -171.57% -63.03% -51.24%

Does the media favor INMD or PROF?

In the previous week, InMode had 1 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for InMode and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat InMode's score of 0.62 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SIBN or PROF?

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 4.24 -$18.90M -$0.34 N/A Profound Medical $16.10M 15.46 -$42.57M -$0.98 N/A

Is SIBN or PROF more profitable?

SiBone has a net margin of -6.85% compared to Profound Medical's net margin of -171.57%. SiBone's return on equity of -8.23% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -6.85% -8.23% -6.07% Profound Medical -171.57% -63.03% -51.24%

Does the media prefer SIBN or PROF?

In the previous week, SiBone had 4 more articles in the media than Profound Medical. MarketBeat recorded 6 mentions for SiBone and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat SiBone's score of 0.66 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PROF or AVR?

In the previous week, Anteris Technologies Global had 5 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for Anteris Technologies Global and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat Anteris Technologies Global's score of 1.17 indicating that Profound Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anteris Technologies Global 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Profound Medical (PROF) Competitors

$6.85 -0.11 (-1.58%)

As of 08/28/2026 04:00 PM Eastern

Compare

PROF vs. CBLL, BBNX, INMD, SIBN, and AVR

Should you buy Profound Medical stock or one of its competitors? Profound Medical's main competitors and comparable companies include CeriBell (CBLL), Beta Bionics (BBNX), InMode (INMD), SiBone (SIBN), and Anteris Technologies Global (AVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Profound Medical compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

47.9% of Profound Medical shares are owned by institutional investors. 17.7% of CeriBell shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CeriBell has a net margin of -64.73% compared to Profound Medical's net margin of -171.57%. CeriBell's return on equity of -44.85% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
Profound Medical	-171.57%	-63.03%	-51.24%

In the previous week, CeriBell had 16 more articles in the media than Profound Medical. MarketBeat recorded 18 mentions for CeriBell and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat CeriBell's score of 0.78 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Profound Medical has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	10.23	-$53.41M	-$1.76	N/A
Profound Medical	$16.10M	15.46	-$42.57M	-$0.98	N/A

CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

CeriBell currently has a consensus price target of $22.40, indicating a potential downside of 5.60%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 67.88%. Given Profound Medical's higher possible upside, analysts clearly believe Profound Medical is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

CeriBell beats Profound Medical on 9 of the 15 factors compared between the two stocks.

How does Profound Medical compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Beta Bionics has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Beta Bionics has a net margin of -61.31% compared to Profound Medical's net margin of -171.57%. Beta Bionics' return on equity of -26.30% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Profound Medical	-171.57%	-63.03%	-51.24%

47.9% of Profound Medical shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Beta Bionics had 2 more articles in the media than Profound Medical. MarketBeat recorded 4 mentions for Beta Bionics and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat Beta Bionics' score of 0.55 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Profound Medical has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	8.85	-$73.20M	-$1.65	N/A
Profound Medical	$16.10M	15.46	-$42.57M	-$0.98	N/A

Beta Bionics presently has a consensus target price of $20.10, suggesting a potential upside of 1.93%. Profound Medical has a consensus target price of $11.50, suggesting a potential upside of 67.88%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Beta Bionics and Profound Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Profound Medical compare to InMode?

InMode (NASDAQ:INMD) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

68.0% of InMode shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

InMode has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 7.74%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 67.88%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

InMode has a net margin of 20.69% compared to Profound Medical's net margin of -171.57%. InMode's return on equity of 11.99% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
Profound Medical	-171.57%	-63.03%	-51.24%

In the previous week, InMode had 1 more articles in the media than Profound Medical. MarketBeat recorded 3 mentions for InMode and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat InMode's score of 0.62 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.30	$93.83M	$1.23	12.07
Profound Medical	$16.10M	15.46	-$42.57M	-$0.98	N/A

Summary

InMode beats Profound Medical on 10 of the 15 factors compared between the two stocks.

How does Profound Medical compare to SiBone?

SiBone (NASDAQ:SIBN) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	4.24	-$18.90M	-$0.34	N/A
Profound Medical	$16.10M	15.46	-$42.57M	-$0.98	N/A

SiBone currently has a consensus price target of $24.17, indicating a potential upside of 25.80%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 67.88%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

98.1% of SiBone shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SiBone has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

In the previous week, SiBone had 4 more articles in the media than Profound Medical. MarketBeat recorded 6 mentions for SiBone and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat SiBone's score of 0.66 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has a net margin of -6.85% compared to Profound Medical's net margin of -171.57%. SiBone's return on equity of -8.23% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Profound Medical	-171.57%	-63.03%	-51.24%

Summary

SiBone beats Profound Medical on 11 of the 16 factors compared between the two stocks.

How does Profound Medical compare to Anteris Technologies Global?

Profound Medical (NASDAQ:PROF) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Profound Medical currently has a consensus target price of $11.50, indicating a potential upside of 67.88%. Anteris Technologies Global has a consensus target price of $16.00, indicating a potential upside of 83.07%. Given Anteris Technologies Global's higher possible upside, analysts clearly believe Anteris Technologies Global is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Profound Medical has higher revenue and earnings than Anteris Technologies Global. Profound Medical is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.46	-$42.57M	-$0.98	N/A
Anteris Technologies Global	$1.91M	445.97	-$94.14M	-$1.95	N/A

In the previous week, Anteris Technologies Global had 5 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for Anteris Technologies Global and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 1.28 beat Anteris Technologies Global's score of 1.17 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anteris Technologies Global	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Profound Medical has a net margin of -171.57% compared to Anteris Technologies Global's net margin of -4,619.27%. Profound Medical's return on equity of -63.03% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-171.57%	-63.03%	-51.24%
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%

Summary

Profound Medical beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$248.94M	$5.88B	$7.21B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.28%
P/E Ratio	N/A	21.48	212.62	21.91
Price / Sales	15.46	68.66	625.86	92.63
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	3.74	6.18	11.08	6.36
Net Income	-$42.57M	$149.94M	$3.48B	$349.79M
7 Day Performance	0.88%	-0.24%	0.13%	-0.80%
1 Month Performance	-5.52%	6.18%	7.08%	4.13%
1 Year Performance	53.24%	6.30%	24.67%	15.17%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	2.1914 of 5 stars	$6.85 -1.6%	$11.50 +67.9%	+53.2%	$248.94M	$16.10M	N/A	150	Positive News
CBLL CeriBell	1.2145 of 5 stars	$23.95 +0.0%	$22.40 -6.5%	+100.6%	$918.77M	$89.06M	N/A	N/A	Insider Trade
BBNX Beta Bionics	1.1913 of 5 stars	$19.34 -2.0%	$20.10 +3.9%	+4.7%	$887.65M	$100.25M	N/A	294
INMD InMode	1.3747 of 5 stars	$15.03 -0.5%	$16.00 +6.5%	-0.6%	$867.96M	$370.49M	12.22	480
SIBN SiBone	2.373 of 5 stars	$19.54 +0.4%	$24.17 +23.7%	+15.2%	$863.48M	$200.93M	N/A	350	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. CBLL, BBNX, INMD, SIBN, and AVR

How does Profound Medical compare to CeriBell?

Summary

How does Profound Medical compare to Beta Bionics?

Summary

How does Profound Medical compare to InMode?

Summary

How does Profound Medical compare to SiBone?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. CBLL, BBNX, INMD, SIBN, and AVR

How does Profound Medical compare to CeriBell?

Do institutionals & insiders hold more shares of CBLL or PROF?

Is CBLL or PROF more profitable?

Does the media favor CBLL or PROF?

Which has higher earnings and valuation, CBLL or PROF?

Which has more risk & volatility, CBLL or PROF?

Do analysts rate CBLL or PROF?

Summary

How does Profound Medical compare to Beta Bionics?

Which has more volatility and risk, BBNX or PROF?

Is BBNX or PROF more profitable?

Do institutionals and insiders hold more shares of BBNX or PROF?

Does the media prefer BBNX or PROF?

Which has higher earnings & valuation, BBNX or PROF?

Do analysts prefer BBNX or PROF?

Summary

How does Profound Medical compare to InMode?

Do insiders and institutionals hold more shares of INMD or PROF?

Which has more volatility & risk, INMD or PROF?

Do analysts prefer INMD or PROF?

Is INMD or PROF more profitable?

Does the media favor INMD or PROF?

Which has preferable valuation & earnings, INMD or PROF?

Summary

How does Profound Medical compare to SiBone?

Which has stronger valuation and earnings, SIBN or PROF?

Do analysts recommend SIBN or PROF?

Do institutionals and insiders believe in SIBN or PROF?

Which has more volatility & risk, SIBN or PROF?

Does the media prefer SIBN or PROF?

Is SIBN or PROF more profitable?

Summary

How does Profound Medical compare to Anteris Technologies Global?

Do analysts recommend PROF or AVR?

Do institutionals & insiders believe in PROF or AVR?

Which has more volatility and risk, PROF or AVR?

Which has preferable valuation and earnings, PROF or AVR?

Does the media refer more to PROF or AVR?

Is PROF or AVR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools